20:21 , Aug 9, 2019 |  BioCentury  |  Finance

Stem cells (re)generate rewards for Versant, Bayer

The combination of stem cells, gene therapy and regenerative medicine was not in vogue in 2016, but Versant and Bayer felt it had enough promise to make a bet on creating and funding BlueRock. Now...
22:49 , Jul 25, 2019 |  BC Innovations  |  Tools & Techniques

New CRISPR case to finally settle the score

The latest CRISPR patent case aims to do what the first didn’t: determine who gets rights to the gene editing technology in eukaryotic cells, a category that covers almost all the cell types that matter...
13:01 , Jul 1, 2019 |  BC Extra  |  Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding. It’s the second time the partners have...
23:58 , Jun 5, 2019 |  BC Extra  |  Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

Pfizer Inc. (NYSE:PFE) hired Jeff Settleman as SVP and group head of oncology R&D, effective July 1. He was head of oncology research at Calico Life Sciences LLC (South San Francisco, Calif.) and prior to...
18:26 , Nov 30, 2018 |  BC Week In Review  |  Company News

Bayer cuts 900 pharma jobs to invest externally

Bayer AG (Xetra:BAYN) plans to increase its investment in external innovations using funds it will save from cutting 900 positions from its pharma division. The company said it will also focus on "collaborative research models."...
00:01 , Nov 30, 2018 |  BC Extra  |  Company News

Bayer cuts 900 pharma jobs to invest externally

Bayer AG (Xetra:BAYN) plans to increase its investment in external innovations using funds it will save from cutting 900 positions from its pharma division. The company said it will also focus on "collaborative research models."...
17:33 , Nov 16, 2018 |  BC Week In Review  |  Company News

MaxCyte partners with Kite, CRISPR in nonviral gene editing deals

MaxCyte Inc. (LSE:MXCT) partnered with Kite Pharma Inc. and expanded an existing deal with CRISPR Therapeutics AG (NASDAQ:CRSP) to use its Flow Electroporation technology to engineer cells. Kite gains a non-exclusive license to use MaxCyte's...
22:38 , Nov 1, 2018 |  BC Extra  |  Company News

Management tracks: CuraSen names Vargas CMO; plus Sosei, Casebia

Neurodegenerative disease start-up CuraSen Therapeutics Inc. (San Mateo, Calif.) hired Gabriel Vargas as its first CMO. Vargas led early development of migraine prophylactic Aimovig erenumab at Amgen Inc. (NASDAQ:AMGN), where he was most recently executive...
22:33 , Oct 4, 2018 |  BC Innovations  |  Tools & Techniques

No crisp upper hand in CRISPR

While the most recent ruling in the ongoing CRISPR IP battle maintained the Broad Institute’s dominant patent position in the U.S., University of California Berkeley’s dominant position in Europe, coupled with the looming possibility of...
19:28 , Jun 15, 2018 |  BC Week In Review  |  Financial News

AAV plasmid company StrideBio raises $15.7M series A

StrideBio Inc. (Durham, N.C.) raised $15.7 million in a series A round led by existing investor Hatteras Venture Partners with participation from new investors Takeda Ventures, UCB Ventures and Alexandria Venture Investments. StrideBio COO Richard...